49 completed, 14 unknown, 2 terminated. 65 Phase 3, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 65 | Completed 49, Unknown 14, Terminated 2 |
| Phase 2 | 13 | Completed 7, Unknown 6 |
Follow Sofosbuvir: new trials by email Literature Review of Sofosbuvir trials Research Report on Sofosbuvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children Sofosbuvir 200 MG Oral Tablet plus Daclatasvir 30 mg Oral tablets - HCV | Phase 3 | Unknown | Ain Shams University | 30 | 2022-06-05 | 2023-05-11 |
| 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis C Sofosbuvir 400 MG, Ravidasvir 200mg - Hepatitis C | Phase 2 / Phase 3 | Completed | Muhammad Radzi Abu Hassan | 322 | 2021-03-23 | 2025-03-13 |
| Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19) Sofosbuvir 400 MG plus Daclatasvir 200mg - COVID-19 | Phase 3 | Unknown | Mansoura University | 50 | 2020-12-28 | 2021-02-24 |
| Sofosbuvir in Treatment of COVID 19 sofosbuvir, Sofosbuvir ledipsavir, Daclatasvir - COVID | Phase 2 / Phase 3 | Unknown | Tanta University | 60 | 2020-08-01 | 2020-12-08 |
| Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients Sofosbuvir, Daclatasvir - Covid19 | Phase 2 / Phase 3 | Unknown | Tanta University | 100 | 2020-07-01 | 2020-12-03 |
| Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19 Hydroxychloroquine , Sofosbuvir, daclatasvir, Standard of care treatment - COVID-19 | Phase 2 / Phase 3 | Unknown | Cairo University | 100 | 2020-07-01 | 2020-06-25 |
| Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment Sofosbuvir plus Ledipasvir - Covid19 | Phase 3 | Completed | Almaza Military Fever Hospital | 250 | 2020-04-15 | 2020-08-28 |
| Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients Sofosbuvir , daclatasvir, Placebos - Chronic Hepatitis c | Phase 3 | Unknown | Assiut University | 50 | 2019-09-01 | 2019-09-12 |
| Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C | Phase 2 / Phase 3 | Completed | Ohio State University | 54 | 2019-03-22 | 2023-09-13 |
| Safety of Sofosbuvir in People With Advanced Kidney Failure Sofosbuvir, Daclatasvir 60 mg - Kidney Failure, Chronic, Hepatitis C | Phase 3 | Completed | Sanjay Gandhi Postgraduate Institute of Medical Sciences | 30 | 2019-03-15 | 2021-04-06 |
| Study of Seraprevir in Combination With Sofosbuvir in Chronic Genotype 1 Hepatitis C Virus Infection Patients Seraprevir, Sofosbuvir - Hepatitis C Virus Infection | Phase 3 | Unknown | Ginkgopharma CO., LTD | 206 | 2018-10-17 | 2019-06-28 |
| Phase 3 Study of Yimitasvir Phosphate Capsules SOF, DAG181 - Chronic HCV Infection | Phase 3 | Completed | Sunshine Lake Pharma Co., Ltd. | 362 | 2018-04-17 | 2020-03-18 |
| Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C] Sofosbuvir, Daclatasvir, Pegylated Interferon alfa-2a - Hepatitis C, Chronic | Phase 2 / Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 150 | 2018-02-02 | 2021-05-18 |
| Effect of Direct-acting Antiviral Drugs on Erectile Function Sofosbuvir and Daklatasuvir - Hepatitis C | Phase 3 | Unknown | Sherief Abd-Elsalam | 105 | 2018-01-01 | 2020-10-22 |
| Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus Daclatasvir and sofosbuvir - Chronic HCV Infection | Phase 2 / Phase 3 | Unknown | Ain Shams University | 50 | 2017-12-10 | 2023-03-06 |
| Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination Simvastatin 10mg, sofosbuvir plus daclatasvir - Chronic Hepatitis c, Metabolic Syndrome | Phase 2 / Phase 3 | Completed | Ain Shams University | 100 | 2017-12-01 | 2018-09-20 |
| KW-136 With Sofosbuvir for Chinese Adults With Chronic Hepatitis C KW-136 capsule, Sofosbuvir - Hepatitis C, Chronic | Phase 3 | Completed | Kawin Technology Share-holding Co., Ltd. | 371 | 2017-06-07 | 2019-06-25 |
| Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents 12 weeks (Sofosbuvir 400mg/Ledipasvir 90mg), 8 weeks (Sofosbuvir 400mg/Ledipasvir 90mg) - Hepatitis C Virus Infection, Response to Therapy of | Phase 3 | Unknown | Egyptian Liver Hospital | 80 | 2017-04-15 | 2018-05-24 |
| Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir Combined Therapy SOF and DCV - Hepatitis C Genotype 4 | Phase 3 | Completed | Yassin Abdelghaffar Charity Center for Liver Disease and Research | 40 | 2017-03-18 | 2018-06-06 |
| Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection. SOF/VEL for 6 weeks, SOF/VEL for 12 weeks - Hepatitis C | Phase 3 | Completed | Kirby Institute | 222 | 2017-03-09 | 2021-11-24 |
Showing 20 of 65. Sign in to see all of them.
Hepatitis C (37) · Hepatitis C, Chronic (17) · Fibrosis (6) · COVID-19 (4) · Acquired Immunodeficiency Syndrome (3) · Hepatitis (2) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Hepatocellular (1) · Digestive System Diseases (1) · Directly Observed Therapy (1) · Enterovirus Infections (1) · Flaviviridae Infections (1) · Hepatitis, Chronic (1) · Hepatitis, Viral, Human (1) · Kidney Failure, Chronic (1)
Gilead Sciences (18) · AbbVie (4) · Bristol-Myers Squibb (4) · Ain Shams University (3) · Egyptian Liver Hospital (3) · Humanity and Health Research Centre (3) · Tehran University of Medical Sciences (3) · Janssen Infectious Diseases BVBA (2) · Tanta University (2) · Almaza Military Fever Hospital (1) · Assiut University (1) · Cairo University (1) · Drugs for Neglected Diseases (1) · Ginkgopharma CO., LTD (1) · Iran Hepatitis Network (1)
United States (18) · Egypt (16) · Canada (11) · Australia (10) · Puerto Rico (9) · China (8) · New Zealand (8) · United Kingdom (7) · Germany (6) · France (5) · Italy (5) · Spain (5) · Netherlands (4) · Sweden (4) · India (3)
Anuj Gaggar, MD, PhD (2) · Kathryn Kersey, MSc (2) · Reza Malekzadeh, M.D. (2) · Steven Knox (2) · Ahmed Cordie, lecturer (1) · Aisha El Sharkawy, MD (1) · Amanda Wieland, MD (1) · Amit Goel, DM (1) · Amr Maged (1)
PMID 25040192, PMID 25583164, PMID 23607593, PMID 23607594, PMID 26575258, PMID 27847279, PMID 36740893, PMID 17593061, PMID 17635375, PMID 17850410, PMID 18266997, PMID 19053983, PMID 24316172, PMID 24795201, PMID 25038354, PMID 25614962, PMID 25659285, PMID 25863559, PMID 26196502, PMID 26248087, PMID 26503414, PMID 26743093, PMID 26799692, PMID 26835876, PMID 26864153, PMID 27025835, PMID 27188960, PMID 27376706, PMID 27542322, PMID 27896822, PMID 27933698, PMID 28935432, PMID 29180522, PMID 29344726, PMID 29404492, PMID 29461687, PMID 29727383, PMID 30012435, PMID 30529905, PMID 30587935, PMID 30868245, PMID 30923816, PMID 30977945, PMID 31568620, PMID 31999307, PMID 32367815, PMID 33633233, PMID 33865507, PMID 33930223, PMID 34023350
2014 (4), 2015 (1), 2016 (1), R01DA026727 (1), UL1TR001082 (1)